Drug Trial Radar · NCT00006249
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
Last checked: Nov 19, 2026Latest source record: Feb 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,258
Actual
Start
Jun 2000
Primary completion
Aug 2003
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma. PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.
Conditions
- Melanoma (Skin)
Interventions
pegylated interferon alfaBiological
adjuvant therapyProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- distant-metastasis free-survival (DMFS)Time frame: from randomization
Locations
104 sites in 18 countries. Site status is shown where the registry gives one.
David Maddison Clincial Sciences
Newcastle, Australia
Peter MacCallum Cancer Institute
East Melbourne, Victoria, Australia
Austin and Repatriation Medical Centre
Heidelberg West, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Sir Charles Gairdner Hospital, Perth
Perth, Western Australia, Australia
Institut Jules Bordet
Brussels, Belgium
Hopital Universitaire Erasme
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Clinique Notre Dame de Grace
Gosselies, Belgium
U.Z. Gasthuisberg
Leuven, Belgium
National Centre of Oncology
Sofia, Bulgaria
University Hospital Sestre Milosrdnice
Zagreb, Croatia
Charles University Hospital
Prague (Praha), Czechia
North-Estonian Regional Hospital Cancer Centre
Tallinn, Estonia
Centre Hospitalier Universitare d'Amens
Amiens, France
CHR de Besancon - Hopital Saint-Jacques
Besançon, France
Hopital Saint Andre
Bordeaux, France
CHU Ambroise Pare
Boulogne-Billancourt, France
CHR de Grenoble - La Tronche
Grenoble, France
Centre Hospitalier Regional et Universitaire de Lille
Lille, France
Centre Hospital Regional Universitaire de Limoges
Limoges, France
Centre Leon Berard
Lyon, France
Hopital St. Eloi
Montpellier, France
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France
Hopital L'Archet - 2
Nice, France
Hopital Bichat - Claude Bernard
Paris, France
Hopital Saint-Louis
Paris, France
Hopital Haut Leveque
Pessac, France
Centre Hospitalier Universitaire
Reims, France
Centre Eugene Marquis
Rennes, France
Centre Rene Huguenin
Saint-Cloud, France
Centre Hospitalier Regional et Universitaire de Saint-Etienne
Saint-Priest-en-Jarez, France
Hopitaux Universitaire de Strasbourg
Strasbourg, France
Centre Hospitalier Regional Metz Thionville
Thionville, France
Centre Hospitalier Universitaire Bretonneau de Tours
Tours, France
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, France
Institut Gustave Roussy
Villejuif, France
Robert Roessle Klinik
Berlin, Germany
Saint Josef Hospital
Bochum, Germany
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.